Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 2/20 | 0.62 |
| ▸ | CDK9 | P50750 | 2/20 | 0.62 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.56 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2268299 | 0.85 | CCNT1 (0.62) | CCNT1CDK9HASPINCYP2A6IMPDH2 | |
| SCHEMBL29664462 | 0.85 | CCNT1 (0.62) | CCNT1CDK9HASPINCYP2A6IMPDH2 | |
| Hydrochloric Acid SCHEMBL3831446 | 0.84 | CCNT1 (0.60) | CCNT1CDK9HASPINCYP2A6IMPDH2 | |
| SCHEMBL28321030 | 0.81 | HTR6 (0.47) | CCNT1CDK9HASPINIMPDH2HTR6 | |
| SCHEMBL29954562 | 0.75 | CCNT1 (0.58) | CCNT1CDK9HASPINCYP2A6IMPDH2 | |
| SCHEMBL3459147 | 0.74 | CCNT1 (0.56) | CCNT1CDK9HASPINCYP2A6IMPDH2 | |
| 3-Formylindole SCHEMBL29082887 | 0.74 | CYP2A6 (0.77) | CCNT1CDK9HASPINCYP2A6IMPDH2 | |
| SCHEMBL23600366 | 0.74 | CGAS (0.51) | CCNT1CDK9HASPINKMT2AHTR6 | |
| SCHEMBL6755476 | 0.74 | APP (0.63) | CCNT1CDK9HASPINKMT2AHTR6 | |
| SCHEMBL23582847 | 0.73 | PIM1 (0.38) | CCNT1CDK9HASPINKMT2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090330-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3440097-B1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2024-10-23 | — | — | EP | disclosed |
| US-12012411-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-18 | — | — | US | disclosed |
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| CN-110526854-B | Alpha, beta-unsaturated ketone derivative, preparation method and application thereof as medicine | 宁夏医科大学 | 2023-12-15 | — | — | CN | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| WO-2023154314-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-4212515-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| WO-2017176608-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-12 | — | — | WO | disclosed |
| US-20170283463-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-10-05 | — | — | US | disclosed |
| US-20170283463-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-10-05 | — | — | US | disclosed |
| US-20170283463-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-10-05 | — | — | US | disclosed |
| CN-104024223-A | Inhibitors of viral replication | UNIV LEUVEN KATH | 2014-09-03 | — | — | CN | disclosed |
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-07-31 | — | — | US | disclosed |
| US-8003649-B2 | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| EP-2235010-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| WO-2009081197-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | CCNT1 1828/4885CDK9 330/4885HASPIN 815/4885 |
| US-20170283463-A1 | IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | CCNT1 2034/4885CDK9 2002/4885HASPIN 398/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | CCNT1 4702/4885CDK9 3876/4885HASPIN 4644/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CCNT1 3710/4885CDK9 2494/4885HASPIN 4671/4885 |
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | CCNT1 781/4885CDK9 346/4885HASPIN 1643/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | CCNT1 3710/4885CDK9 2494/4885HASPIN 4671/4885 |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | AR, NR5A1, CYP17A1 | CCNT1 1437/4885CDK9 2178/4885HASPIN 3025/4885 |
| US-12012411-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | CCNT1 781/4885CDK9 346/4885HASPIN 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.